News & Announcements
|
March 9, 2021 - Claritas Rx Announces Significant Growth Equity Investment from Questa Capital
Claritas Rx, the leading provider of data and analytics solutions covering specialty and rare disease patients, today announced the closing of a significant growth equity investment from Questa Capital, a venture growth equity firm focused on investing in expansion-stage healthcare companies. The funds will be used to enhance drug and patient analytics with innovative new products, accelerate sales & marketing, and expand the company’s management team. “Claritas is illuminating the patient journey every day, revealing opportunities for our pharma clients and the broader specialty ecosystem to support patients in managing their chronic, life sustaining therapies. This funding will allow us to invest in our existing client relationships, as well as accelerate product innovation, and expand our market reach. We are thrilled to have a partner like Questa with deep healthcare domain expertise and appreciation for our mission of using real world data to illuminate the patient journey,” said Mike Fitzgibbons, Claritas Rx Founder and Chief Executive Officer. Read the press release here. September 14, 2020 - Claritas Rx And Turning Point Form Partnership on Specialty Pharmacy Analytics
Claritas Rx, a data integration and analytics company focused on specialty biopharmaceutical distribution channels, announced today that it has partnered with Turning Point, an innovative specialty pharmacy network comprised of the largest independent, top-performing specialty pharmacies, to provide biopharmaceutical manufacturers in-depth analytics and insight based on data from the Turning Point specialty pharmacy network. "Claritas is the perfect partner due to the cultural fit and expertise," said Erik Halstrom, Managing Director of Turning Point. "The partnership combines Turning Point data with Claritas' analytics providing manufacturers longitudinal insight into how patients experience treatment milestones across a therapeutic category. Providing manufacturers with faster, more actionable competitive insight and better forecasting, with visibility before and after treatment initiation, is so important as manufacturers look at market dynamics in their therapeutic categories." Read the press release here. |
|
©2021 Claritas Rx, Inc. All rights reserved.
|